Krystal Biotech, Inc. (FRA:4KB)

Market Cap	6.52B
Revenue (ttm)	318.05M
Net Income (ttm)	169.53M
Shares Out	n/a
EPS (ttm)	5.68
PE Ratio	38.44
Forward PE	31.01
Dividend	n/a
Ex-Dividend Date	n/a

Volume	59
Average Volume	6
Open	216.40
Previous Close	207.50
Day's Range	214.00 - 216.40
52-Week Range	108.40 - 216.20
Beta	n/a
RSI	66.82
Earnings Date	Feb 13, 2026

About Krystal Biotech

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 cl...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2016
• Employees: 275
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4KB

Financial Performance

In 2024, Krystal Biotech's revenue was $290.52 million, an increase of 473.02% compared to the previous year's $50.70 million. Earnings were $89.16 million, an increase of 715.58%.

Financial numbers in USD